ストックスクリーナーアプリを入手
1.18
39.63%
0.3349
アフターアワーズ：
1.11
-0.07
-5.93%
前日終値:
$0.8451
開ける：
$0.8107
24時間の取引高:
4.44M
Relative Volume:
2.46
時価総額：
$6.60M
収益：
-
当期純損益:
$-13.52M
株価収益率:
-1.5946
EPS:
-0.74
ネットキャッシュフロー:
$-10.03M
1週間 パフォーマンス:
+38.59%
1か月 パフォーマンス:
-6.36%
6か月 パフォーマンス:
-68.24%
1年 パフォーマンス:
-46.34%
1日の値動き範囲:
$0.80
$1.44
1週間の範囲:
$0.756
$1.44
52週間の値動き範囲:
$0.756
$15.80
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
名前
Kazia Therapeutics Limited Adr
セクター
電話
01161298780088
住所
140 WICKS RD, NEW SOUTH WALES 2113, NSW
KZIA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
1.18 | 6.60M | 0 | -13.52M | -10.03M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.29 | 125.39B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
707.51 | 77.35B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.21 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
244.52 | 31.65B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
247.07 | 26.47B | 3.32B | -860.46M | -1.04B | -8.32 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-06 | 開始されました | Maxim Group | Buy |
| 2021-10-14 | 開始されました | Maxim Group | Buy |
| 2021-01-05 | 開始されました | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr (KZIA) 最新ニュース
SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease - BioSpace
Kazia explores paxalisib for Parkinson's with MJFF grant - Investing.com
Kazia Therapeutics Awarded Research Grant to Explore Paxalisib’s Potential for Parkinson’s Treatment - TipRanks
KZIA’s Stock Journey: What Investors Need to Know About Kazia Therapeutics Limited ADR’s Performance - The InvestChronicle
Kazia Therapeutics Limited ADR (KZIA) Stock: Analyzing the Market Value - The News Heater
SolarBank Corporation (SUUN) Stock: Evaluating the Market Performance - The News Heater
Aditxt Inc (ADTX) Stock: A Look at the Analyst Recommendations - The News Heater
Maxim Group Begins Coverage on Kazia Therapeutics (NASDAQ:KZIA) - Defense World
10 Best ASX Stocks to Buy According to Hedge Funds - Insider Monkey
Game-Changing Cancer Trial: Kazia's New Drug Combo Could Unmask Hidden Breast Cancer Cells - StockTitan
Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now? - Insider Monkey
10 Best Australian Stocks to Buy Now - Insider Monkey
Kazia Therapeutics Secures $2M Funding Through Direct Offering to Alumni Capital - StockTitan
Kazia Therapeutics secures $2 million in direct offering - Investing.com India
Kazia Therapeutics Secures $2M Funding Through Direct Offering at $1.50 Per ADS - StockTitan
Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday? - Yahoo Finance
Kazia aligns with FDA on glioblastoma drug study design - Investing.com India
Kazia's Brain Cancer Drug Paxalisib Shows 3.8-Month Survival Benefit, FDA Guides Phase 3 Path Forward - StockTitan
Kazia's Paxalisib Shows Promise in Breast Cancer Trial: Key Data Released at SABCS - StockTitan
Kazia sets FDA meeting for glioblastoma drug pathway - Investing.com India
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme - StockTitan
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested - Nasdaq
Best upcoming stock splits and reverse splits 2024 - InvestorsObserver
Ratios in Focus: Analyzing Kazia Therapeutics Limited ADR (KZIA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing - Yahoo Finance
Kazia Therapeutics Stock Scheduled to Reverse Split on Monday, October 28th (NASDAQ:KZIA) - Defense World
B2i Digital Acting as Marketing Partner for Maxim Group's 2024 Healthcare Virtual Summit - Benzinga
Paxalisib shows promise in brain metastasis treatment - Investing.com
It makes sense and dollars to buy Kazia Therapeutics Limited ADR (KZIA) stock - SETE News
Market Recap: Kazia Therapeutics Limited ADR (KZIA)’s Positive Momentum, Closing at 0.43 - The Dwinnex
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American - StockTitan
Kazia Therapeutics Limited ADR (KZIA) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Kazia Therapeutics Limited ADR (KZIA) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
China Vanke Co., Ltd. (OTCMKTS:CHVKY) Short Interest Update - Defense World
Kazia Therapeutics (NASDAQ:KZIA) Stock Price Down 3.6% - Defense World
KZIAKazia Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium - StockTitan
Immunotherapy Clinical TrialsA New Approach to Treating Cancer - StockTitan
The Psychology of Kazia Therapeutics Limited ADR Inc. (KZIA) Price Performance: Understanding Market Sentiment - The InvestChronicle
Financial Health Report: Kazia Therapeutics Limited ADR (KZIA)’s Ratios Tell a Tale - The Dwinnex
Take off with Kazia Therapeutics Limited ADR (KZIA): Get ready for trading - SETE News
Did Kazia Therapeutics Limited ADR (KZIA) perform well in the last session? - US Post News
Kazia Therapeutics Limited Adr (KZIA) 財務データ
収益
当期純利益
現金流量
EPS
1.43%
0.81%
大文字化:
|
ボリューム (24 時間):